Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:ARCT NYSE:BHVN NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$63.93+0.9%$64.00$52.50▼$77.00$1.37B0.57303,297 shs318,815 shsARCTArcturus Therapeutics$12.30+0.7%$13.17$8.04▼$25.88$333.59M2.26381,998 shs361,584 shsBHVNBiohaven$14.77-2.2%$14.70$12.79▼$55.70$1.54B0.981.82 million shs2.46 million shsTVTXTravere Therapeutics$15.63+1.2%$15.31$7.93▼$25.29$1.37B0.741.19 million shs764,859 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.92%-5.26%-1.98%-12.36%-2.72%ARCTArcturus Therapeutics+0.74%-17.67%-9.69%-4.13%-47.57%BHVNBiohaven-1.88%+9.45%0.00%-35.11%-62.45%TVTXTravere Therapeutics+1.17%+2.02%+5.32%-26.10%+63.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.7646 of 5 stars2.51.00.03.33.23.31.3ARCTArcturus Therapeutics3.0347 of 5 stars3.62.00.00.03.72.50.6BHVNBiohaven2.3606 of 5 stars3.51.00.00.02.42.50.6TVTXTravere Therapeutics1.9209 of 5 stars3.41.00.00.02.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$78.8823.38% UpsideARCTArcturus Therapeutics 3.11Buy$54.00339.02% UpsideBHVNBiohaven 3.07Buy$58.46295.81% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$32.14105.65% UpsideCurrent Analyst Ratings BreakdownLatest ARCT, ANIP, BHVN, and TVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$84.007/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.007/1/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$30.006/18/2025BHVNBiohavenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.006/11/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$30.006/11/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $32.005/28/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$32.005/19/2025BHVNBiohavenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/16/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/16/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$674.07M2.05$7.67 per share8.34$19.11 per share3.35ARCTArcturus Therapeutics$131.27M2.54N/AN/A$8.90 per share1.38BHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/ATVTXTravere Therapeutics$233.18M5.95N/AN/A$0.76 per share20.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.19N/A-3.12%21.35%7.52%8/5/2025 (Estimated)ARCTArcturus Therapeutics-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/11/2025 (Estimated)BHVNBiohaven-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%8/6/2025 (Confirmed)Latest ARCT, ANIP, BHVN, and TVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q1 2025BHVNBiohaven-$1.94N/AN/AN/AN/AN/A8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11N/AN/AN/A$17.64 millionN/A8/6/2025Q2 2025TVTXTravere Therapeutics-$0.26N/AN/AN/A$100.18 millionN/A8/5/2025Q2 2025ANIPANI Pharmaceuticals$1.49N/AN/AN/A$187.18 millionN/A5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AARCTArcturus Therapeutics$0.715.81%N/AN/A N/ABHVNBiohavenN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98ARCTArcturus Therapeutics0.065.645.64BHVNBiohavenN/A2.332.33TVTXTravere Therapeutics9.462.052.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%ARCTArcturus Therapeutics94.54%BHVNBiohaven88.78%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%ARCTArcturus Therapeutics16.60%BHVNBiohaven16.00%TVTXTravere Therapeutics4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million19.26 millionOptionableARCTArcturus Therapeutics18027.12 million22.62 millionOptionableBHVNBiohaven239102.11 million85.78 millionOptionableTVTXTravere Therapeutics46088.81 million85.08 millionOptionableARCT, ANIP, BHVN, and TVTX HeadlinesRecent News About These CompaniesTravere Therapeutics (TVTX) Expected to Announce Earnings on ThursdayJuly 31 at 3:19 AM | marketbeat.comTravere Therapeutics to Report Second Quarter 2025 Financial ResultsJuly 30 at 4:44 PM | businesswire.comEssex Investment Management Co. LLC Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)July 29, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Has $6.07 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)July 28, 2025 | marketbeat.com32,731 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Acquired by Legato Capital Management LLCJuly 26, 2025 | marketbeat.comBank of New York Mellon Corp Boosts Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX)July 26, 2025 | marketbeat.comJennison Associates LLC Increases Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)July 21, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 18, 2025 | marketbeat.comWedbush Forecasts Reduced Earnings for Travere TherapeuticsJuly 17, 2025 | marketbeat.comWedbush Expects Lower Earnings for Travere TherapeuticsJuly 16, 2025 | marketbeat.comEmerald Advisers LLC Lowers Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)July 13, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Increases Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)July 12, 2025 | marketbeat.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 | businesswire.com109,542 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Penserra Capital Management LLCJuly 8, 2025 | marketbeat.comLeerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)July 6, 2025 | insidermonkey.comLeerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)July 6, 2025 | msn.comInsider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 815 Shares of StockJuly 3, 2025 | insidertrades.comQ2 EPS Estimate for Travere Therapeutics Cut by AnalystJuly 3, 2025 | marketbeat.comJula Inrig Sells 815 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) StockJuly 2, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXJuly 2, 2025 | prnewswire.com1TVTX : Demystifying Travere Therapeutics: Insights From 8 Analyst ReviewsJuly 2, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCT, ANIP, BHVN, and TVTX Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$63.93 +0.58 (+0.92%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$63.55 -0.38 (-0.59%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Arcturus Therapeutics NASDAQ:ARCT$12.30 +0.09 (+0.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$12.61 +0.31 (+2.52%) As of 08/1/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Biohaven NYSE:BHVN$14.77 -0.33 (-2.19%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$14.59 -0.18 (-1.25%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Travere Therapeutics NASDAQ:TVTX$15.63 +0.18 (+1.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.23 -0.40 (-2.56%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
